Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
0.8412
-0.0470 (-5.29%)
Streaming Delayed Price
Updated: 9:54 AM EST, Nov 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
19,529
Open
0.8813
Bid (Size)
0.8412 (9)
Ask (Size)
0.8839 (3)
Prev. Close
0.8882
Today's Range
0.8403 - 0.8876
52wk Range
0.7043 - 11.41
Shares Outstanding
41,957,197
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Upgrades For Wednesday
November 06, 2024
Via
Benzinga
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
November 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Performance
YTD
-87.65%
-87.65%
1 Month
-46.42%
-46.42%
3 Month
-71.58%
-71.58%
6 Month
-90.33%
-90.33%
1 Year
-77.33%
-77.33%
More News
Read More
S&P 500 Gains 1%; Vimeo Shares Spike Higher
November 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 05, 2024
Via
Benzinga
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 05, 2024
Via
Benzinga
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
November 05, 2024
Via
Benzinga
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
November 04, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
10 Health Care Stocks Moving In Monday's Pre-Market Session
November 04, 2024
Via
Benzinga
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
October 24, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
October 11, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 03, 2024
Via
Benzinga
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
October 03, 2024
Via
Benzinga
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
October 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
September 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
September 04, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
August 27, 2024
Via
Benzinga
Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
August 14, 2024
Via
Benzinga
Exposures
Fossil Fuels
Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
August 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
Via
InvestorPlace
US Stocks Mixed; Inflation Rate Falls More Than Projected
August 14, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
August 14, 2024
Via
Benzinga
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
August 14, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.